April 2025 PCWHS
All interpretations should be reviewed with a qualified healthcare provider
TOM BRADY TEAMS WITH DIGITAL HEALTH FIRM EMED TO EXPAND GLP-1 WEIGHT LOSS MEDICATION ACCESS Meanwhile, Lilly rejected the claims and said its ads are based on its SURMOUNT-5 trial, completed in 2024, which compared patients taking 10 mg or 15 mg of Zepbound with those taking 1.7 mg or 2.4 mg of Wegovy
Some of these products are labeled research chemicals and marked not for human consumption, yet are openly marketed to people seeking weight loss
Doses: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg Dosing: Youll start at 0.25 mg once a week and increase gradually over several weeks to reach the maintenance dose that has you losing steady weight, 1 to 2 pounds per week, with the fewest side effects
2.3.4 P53 signaling pathway Recently, P53 was discovered to promote cellular ferroptosis by regulating the expression of ferroptosis- related genes Earlier research has indicated that P53 interacts with P53 response elements in the SLC7A11 gene promoter region, suppressing SLC7A11 expression and enhancing the vulnerability of cancer cells to ferroptosis (56)
